Schizophrenia Trial, Recruiting NCT07122531 Sponsor: Université de Sherbrooke Condition: Schizophrenia
Back to Schizophrenia

Schizophrenia Trial, Recruiting

NCT07122531
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been referred to, or have referred themselves to, the PEP (First Episode Psychosis) Clinic in the Estrie region, either as an outpatient or as someone staying in hospital.
  • People who have been taking a second- or third-generation antipsychotic medication at a steady, unchanged dose for at least 4 weeks.
  • People who are able to read and communicate in French or English.
  • People who are able to understand and sign a consent form agreeing to take part in the trial.

Who may not be able to join:

  • People who are currently pregnant, have given birth in the last 6 months, or are breastfeeding.
  • People who have used MCT oil, ketone salts, or followed a ketogenic (very low-carbohydrate) diet at any point in the past year.
  • People who have previously been diagnosed with type 1 or type 2 diabetes.
  • People who are experiencing active, uncontrolled thoughts of suicide at the time of joining the PEP clinic.
  • People with other health conditions that a qualified doctor determines could interfere with taking part in the trial.
  • People with pancreatitis (a condition where the pancreas is inflamed) or liver failure.
  • People with a medical condition that affects how the body processes fats, or who have an inherited deficiency in carnitine or its related enzymes.
  • People with a condition called porphyria.
  • People with a condition called pyruvate kinase deficiency.
  • People with a neurodevelopmental disorder of unknown cause, or a rare genetic disease.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Kevin Zemmour, MD, Université de Sherbrooke

Phone: 1-819-821-5206

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Université de Sherbrooke
Registry
ClinicalTrials.gov
Start date
26 August 2025
Est. completion
15 April 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Plasma total ketones concentration; Plasmatic glucose concentration; Plasma Insulin concentraiton; Plasma Glycated hemoglobin

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov